Preventing hepatitis B reactivation after stem cell transplant
Part of Blood & lymphatic, Infections clinical trials.
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 19 to 70 years old
- You are receiving an allogeneic stem cell transplant (from a donor, not your own cells)
- Before transplant, your blood tests show HBsAg negative and anti-HBc IgG positive (past hepatitis B infection)
- You can do daily activities fairly normally (ECOG 0 to 2)
- You agree to join the study (sign informed consent)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an added hepatitis B immune medicine (HBV immunoglobulin) in people with chronic hepatitis B who have liver cancer and are planning surgery or a liver transplant. The goal is to see if giving this protection around the time of treatment can help prevent liver cancer from coming back or worsening.
This study tracks patients who carry hepatitis B antibodies and are about to start immunosuppressive therapy (medications that weaken the immune system). Researchers want to understand when and how hepatitis B can reactivate in these patients and how to prevent it.
This trial checks if measuring a specific virus marker in your blood after a stem cell transplant can help predict or prevent transplant complications. You would have extra blood tests to guide your care.
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
This study helps doctors predict which patients might experience hepatitis B reactivation (a flare-up of a past infection) after receiving a stem cell transplant. By understanding your risk, doctors can monitor you more closely and potentially prevent serious complications.
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
Hear when a new Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.